Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Diagnostic radiopharmaceuticals | 1 |
Radionuclide Drug Conjugates (RDC) | 1 |
Target |
Mechanism NMDA receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. DE |
First Approval Date01 Aug 1997 |
Target |
Mechanism GluN2B modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDE10A inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2023 |
Sponsor / Collaborator |
Start Date17 May 2023 |
Sponsor / Collaborator |
Start Date03 Apr 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Esketamine Hydrochloride ( NMDA receptor ) | Depressive Disorder, Treatment-Resistant More | Phase 3 |
PDE10A inhibitors(Janssen) ( PDE10A ) | Schizophrenia More | Preclinical |
JNJ-77471056 ( GluN2B ) | Alzheimer Disease More | Preclinical |
Dexamethasone ( GR ) | Diffuse Large B-Cell Lymphoma More | Pending |
Terconazole ( fungal CYP51A1 ) | Vaginitis More | Pending |